The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]
Videos
Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]
The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 17, 2022. [WATCH TIME: 4 minutes]
The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]
The director of the Headache Center at Allegheny Health Network provided perspective on whether focusing in on medications or lifestyle choices has better impacts on improving chronic migraine. [WATCH TIME: 4 minutes]
The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]
Advanced practice practitioners share final pearls with their colleagues for the management of sleep disorders.
The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan spoke about the associations of mental health with insomnia in transgender youth. [WATCH TIME: 5 minutes]
Dr Wendy Wright and Debra Davis comment on unmet needs in insomnia and other sleep disorders.
The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan, spoke about sleep disorders associated with transgender youths. [WATCH TIME: 4 minutes]
The professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]
The chief medical officer of Alzheon discussed the impact a therapy like ALZ-801 can have on the overall Alzheimer community considering its effects on carriers of APOE e4 alleles. [WATCH TIME: 3 minutes]
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, discuss their approach to switching treatments for patients with multiple sclerosis and the timing between therapies.
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, share their thoughts on sequencing disease-modifying therapies when treating patients with multiple sclerosis.
Episode 28 of the AUPN Leadership Minute features Donald S. Higgins, MD, of the VHA; and Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN, of University of Oxford. [WATCH TIME: 5 minutes]
The professor of medicine at the University of Manitoba discussed the need to change how multiple sclerosis is characterized, and how aging contributes to increased disease progression. [WATCH TIME: 4 minutes]
The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]
The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]
The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]
Neurology News Network for the week ending December 10, 2022. [WATCH TIME: 4 minutes]
The professor of neurology at Washington University School of Medicine in St. Louis spoke about the field of newborn sleep and epilepsy based on a special lecture from the 2022 AES annual meeting. [WATCH TIME: 3 minutes]
The chief medical officer of Alzheon provided perspective on new phase 2 findings assessing the investigational agent ALZ-801 in patients with early Alzheimer disease and a genetic predisposition. [WATCH TIME: 5 minutes]
Advanced practice practitioners discuss how they assess treatment response and patient adherence in insomnia, and considerations for changing treatment.
Drs Wendy Wright and Debra Davis provide an overview of phase 3 trial data for the most recently FDA-approved DORA, daridorexant, for the treatment of insomnia.
The pediatric epilepsy specialist at Weill Cornell Medicine spoke about how the Pediatric Epilepsy Learning Healthcare System has helped with gathering data at the 2022 AES Conference. [WATCH TIME: 6 minutes]
The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the way to attack Alzheimer agitation and why drug solutions often fall short. [WATCH TIME: 3 minutes]
The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]
The behavioral neurologist at the Barrow Neurological Institute detailed the significance of low rates of ARIA found in lecanemab, and the direction of anti-amyloid therapies in the future. [WATCH TIME: 4 minutes]
The professor of neurology at Washington University in St. Louis, spoke about sleep-wake patterns in epilepsy based on a special lecture from the 2022 AES Annual meeting. [WATCH TIME: 6 minutes]
Advertisement
Advertisement
